Want to see JSPR full AI Analyst Report?
JSPR Stock Chart & Stats
$0.72
-$0.03(-3.63%)
At close: 4:00 PM EDT
$0.72
-$0.03(-3.63%)
Day’s Range― - ―
52-Week Range$0.32 - $2.57
Previous CloseN/A
Volume381.42K
Average Volume (3M)342.82K
Market Cap
$16.63M
Enterprise Value$4.62M
Total Cash (Recent Filing)$7.31M
Total Debt (Recent Filing)$270.00K
Price to Earnings (P/E)―
Beta2.73
Next Earnings
Nov 05, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.59
Shares Outstanding33,274,563
10 Day Avg. Volume370,738
30 Day Avg. Volume342,816
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)8.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.45
Enterprise Value/Market Cap0.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-220.02
Enterprise Value/Ebitda-0.15
Forecast
1Y Price Target
$7.50Price Target Upside941.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.46
Revenue Forecast (FY)$6.00M
Bulls Say, Bears Say
Bulls Say
Phase 2 Renal Pipeline ProgressCompleting enrollment in the IgA nephropathy cohort provides a defined clinical development milestone, while adding a focal segmental glomerulosclerosis cohort broadens testing across complement-mediated kidney diseases. This expands the potential application of vensobafusp alfa and supports pipeline progress over the next several quarters.
Extended Funding RunwayA $132 million PIPE that extends operating runway into the second half of 2028 gives Jasper additional time to advance clinical programs before needing new financing. Greater funding visibility can support trial execution, regulatory work and strategic development while reducing near-term dependence on capital markets.
Potential Dilution ManagementRetiring outstanding warrants can simplify the capital structure and reduce the number of shares that might otherwise be issued through future exercises. Although the action uses cash, limiting this potential dilution may provide existing shareholders with clearer ownership economics as the pipeline advances.
Bears Say
Pre-commercial Business ModelJasper remains pre-commercial, with no product revenue to fund research, clinical development or corporate expenses. Continued losses mean the business has not yet demonstrated operating leverage, and future financial performance remains dependent on clinical progress, regulatory approval and eventual commercialization or partnering.
Persistent Cash BurnSustained negative operating and free cash flow shows that Jasper’s current activities consume capital rather than generate it. Even with improvement from 2025 levels, ongoing burn can require additional financing over time, potentially constraining development choices or increasing shareholder dilution.
Weakening Balance Sheet And Dilution RiskThe sharp decline in equity materially reduces the balance-sheet cushion available to absorb continued losses. The approved increase in authorized shares also gives the company greater financing capacity, but it can raise future dilution risk as Jasper funds development without recurring product revenue.
Jasper Therapeutics News
JSPR FAQ
What was Jasper Therapeutics’s price range in the past 12 months?
Jasper Therapeutics lowest stock price was $0.32 and its highest was $2.57 in the past 12 months.
What is Jasper Therapeutics’s market cap?
Jasper Therapeutics’s market cap is $16.63M.
When is Jasper Therapeutics’s upcoming earnings report date?
Jasper Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 15 days.
How were Jasper Therapeutics’s earnings last quarter?
Jasper Therapeutics released its earnings results on Aug 14, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.268 by $0.168.
Is Jasper Therapeutics overvalued?
According to Wall Street analysts Jasper Therapeutics’s price is currently Undervalued.
Does Jasper Therapeutics pay dividends?
Jasper Therapeutics does not currently pay dividends.
What is Jasper Therapeutics’s EPS estimate?
Jasper Therapeutics’s EPS estimate is -0.06.
How many shares outstanding does Jasper Therapeutics have?
Jasper Therapeutics has 33,274,563 shares outstanding.
What happened to Jasper Therapeutics’s price movement after its last earnings report?
Jasper Therapeutics reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.268. Following the earnings report the stock price went down -8.459%.
Which hedge fund is a major shareholder of Jasper Therapeutics?
Currently, no hedge funds are holding shares in JSPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Jasper Therapeutics
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
JSPR Stock 12 Month Forecast
Average Price Target
$7.50
▲(941.67% Upside)
Technical Analysis
Ownership Overview
1.03%
Insiders
4.31% Mutual Funds
25.00% Other Institutional Investors
66.21% Public Companies and
Individual Investors